CECOG Academy

www.cecog.org

 

CECOG Academy
P

How to Increase the Efficacy of Antiendocrine Treatment of BC: Options and Limitations

By CECOG Academy FEATURING Peter Fasching
By CECOG Academy FEATURING Peter Fasching
0 views
March 29, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy

Featured Video

08:44
Johnson & Johnson

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira
Post ESMO Webinar
11:47
CECOG Academy

Adjuvant Therapies for HER2+ eBC: Trastuzumab & Pertuzumab, T-DM…

Feat. C. Singer
14:05
CECOG Academy

New Adjuvant Therapies for eBC: Olaparib & Talazoparib for BRCA …

Feat. C. Singer
29:38
CECOG Academy

monarchE vs. PALLAS Data on Adjuvant ET in HR+ EBC: What Makes the C…

Feat. A. Awada
22:11
CECOG Academy

How to Increase the Efficacy of Antiendocrine Treatment of BC: Optio…

Feat. P. Fasching
22:31
CECOG Academy

Immune Checkpoint Inhibition in mBC: Does the Chemotherapy Backbone …

Feat. R. Bartsch